Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 1

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 1
---
 (including ordinary shares represented by ADSs) in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of the ordinary shares outstanding immediately after giving effect to such exercise. The ADSs issuable from time to time upon exercise of the pre-funded warrants and warrants are also being offered by this prospectus supplement and the accompanying prospectus. See “Description of Securities We Are Offering” for more information. We refer to the ADSs, the pre-funded warrants and the warrants being offered hereby and the ADSs issued or issuable upon exercise of the pre-funded warrants and the warrants being offered hereby, collectively, as the “securities.” Our ADSs are listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “BLRX.” On January 3, 2025, the closing price of the ADSs on Nasdaq was $0.27 per ADS. Our ordinary shares trade on the Tel Aviv Stock Exchange, or the TASE, under the symbol “BLRX.” On January 5, 2025, the last reported sale price of our ordinary shares on the TASE was NIS 0.076 or $0.021 per share (based on the exchange rate reported by the Bank of Israel on January 3, 2025, which was NIS = $3.656). We do not intend to apply for listing of the pre-funded warrants or warrants on the Nasdaq or any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants and warrants will be limited. Investing in our securities involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well as the information incorporated herein and therein by reference carefully before you make your investment decision. See “Risk Factors” beginning on page S-5 of this prospectus supplement and on page 3 of the accompanying prospectus to read about the factors you should consider before investing in our securities. Neither the Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                     |     | PerADS and Accompanying Warrant |       |     | PerPre-FundedWarrant and Accompanying Warrant |        |     | Total |            |
|:------------------------------------|:----|